argenx Topline Study Results Miss Endpoints

 

• ADDRESS study did not meet primary or secondary endpoints
• Pemphigus deprioritized as efgartigimod indication
• Update on BALLAD study GO/NO GO decision
• Conference call scheduled for today, December 20, 2023, at 8:30am ET (2:30pm CET)

argenx will host a conference call today at 2:30 pm CET (8:30am ET) to discuss the ADDRESS results. A webcast of the live call and replay may be accessed on the Investors section of the argenx website.

Dial-in Numbers:
Please dial in 15 minutes prior to the live call.

Belgium	32 800 50 201
France	33 800 943355
Netherlands	31 20 795 1090
United Kingdom	44 800 358 0970
United States	1 888 415 4250
Japan	81 3 4578 9081
Switzerland	41 43 210 11 32

https://www.globenewswire.com/news-release/2023/12/20/2799009/0/en/argenx-Reports-Topline-Results-from-ADDRESS-Study-of-Efgartigimod-SC-in-Pemphigus.html